Abstracts tagged "cerebrovascular disease and meta-analysis"

Abstract Number: 1480 • 2017 ACR/ARHP Annual Meeting
Risk of Ischemic Stroke in Sjögren’s Syndrome Patients: A Systematic Review and Meta-Analysis
Jirapat Teerakanok¹, Daniel Cordoba², Sakolwan Suchartlikitwong³ and Kenneth Nugent⁴, ¹Internal medicine, Texas Tech University health and sciences center, Lubbock, TX, ²Internal Medicine, Texas Tech University Health and Sciences Center, Lubbock, TX, ³Internal medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ⁴Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX
Background/Purpose: Primary Sjögren’s syndrome (SS) is an autoimmune disease of the exocrine glands with lymphocytic infiltration into lacrimal and salivary glands. Autoimmune diseases increase cardiovascular…
Abstract Number: 1485 • 2017 ACR/ARHP Annual Meeting
Association between Primary Sjogren’s Syndrome, Cardiovascular and Cerebrovascular Events: A Systematic Review and Meta-Analysis
Wai Chung Yong, Anawin Sanguankeo and Sikarin Upala, Bassett Medical Center, Cooperstown, NY
AbstractBackground/Purpose: Studies have demonstrated that acute systemic inflammation and chronic systemic vasculitis are associated with endothelial dysfunction and atherosclerotic plaque formation, subsequently leading to cardiovascular…
Abstract Number: 564 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Events in Ankylosing Spondylitis. an Updated Meta-Analysis
Sylvain Mathieu¹ and Martin Soubrier², ¹Hopital Gabriel Montpied, Clermont Ferrand, France, ²Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France
Background/Purpose: Rheumatoid arthritis is associated with increased cardiovascular risk. In the guidelines, ankylosing spondylitis (AS) is considered to have an equally high cardiovascular risk. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].